NCCN updates guidelines for high-grade prostate cancer

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

A five-year retrospective study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that prostate-specific membrane antigen PET/CT scans can help doctors target treatment more precisely for men whose prostate cancer returns after surgery, improving long-term outcomes and potentially reducing unnecessary side effects.

February 13, 2026

Vol.52 No.06

Clinical Roundup

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

The NCCN added MammaPrint + BluePrint to the Clinical Practice Guidelines in Oncology for the identification of a subset of hormone receptor positive, HER2-negative early-stage breast cancer patients most likely to benefit from anthracycline-based chemotherapy.

February 06, 2026

Vol.52 No.05

Clinical Roundup

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the placebo in men receiving hormone therapy for prostate cancer.

February 06, 2026

Vol.52 No.05

Clinical Roundup

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

January 30, 2026

Vol.52 No.04

Drugs & Targets

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.

January 30, 2026

Vol.52 No.04

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

Vol.52 No.03

By Tanya Dorff

NCCN updates guidelines for high-grade prostate cancer

YOU MAY BE INTERESTED IN

Advanced PET/CT imaging can improve long-term outcomes in recurrent prostate cancer, UCLA-led study finds

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

Oxybutynin reduces hot flashes during prostate cancer treatment, randomized study finds

UCLA launches trial comparing two types of PSMA radiopharmaceuticals for recurrent prostate cancer

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Renew today!

Subscriber content

Never miss an issue!

Login